Patents Examined by Jennifer Berrios
  • Patent number: 11052030
    Abstract: A method of preparing a fine oil-in-water emulsion comprising an oil phase based on silicone and/or hydrocarbon oils, in which the oil phase particles have an average particle size of 150 nm or less. The emulsion is stabilized by a carboxy-modified silicone in combination with a C16 to 22 higher alcohol; a nonionic surfactant having a POE chain and an HLB of 5 to 10; and a dihydric glycol. The emulsions can be prepared without the use of a high-pressure emulsifying apparatus.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: July 6, 2021
    Assignee: SHISEIDO COMPANY, LTD.
    Inventors: Makoto Uyama, Reiji Miyahara
  • Patent number: 11013680
    Abstract: To provide a makeup-protecting material that has an excellent color migration prevention effect, causes no color bleeding over time, gives no coating film appearing whitish, and gives no squeaky or burdensome feeling. A makeup-protecting material comprises (A) 80 to 95% by mass of trifluoropropylcyclopolysiloxane, (B) a fluorine compound-treated silica, and (C) 2 to 8% by mass of a partially crosslinked, fluorine-modified organopolysiloxane polymer.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: May 25, 2021
    Assignee: KOSE CORPORATION
    Inventors: Ryuta Azuma, Ryo Kakimoto, Emi Naru
  • Patent number: 11000034
    Abstract: A controlled-release material sensitive and response to fouling organisms for an antifouling agent includes an encapsulating precursor and a crosslinking agent. A hyaluronic acid/polyL-lysine nano-shell controlled-release material is prepared by an alternating layer-by-layer self-assembly of hyaluronic acid and poly-L-lysine, and a polypropylene ammonium chloride/poly-L-glycine nano-shell controlled-release material is prepared by an alternating layer-by-layer sell-assembly of polypropylene ammonium chloride and poly-L-glycine. The crosslinking agent is composed of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxythiosuccinimide. Based on the specific catalytic hydrolysis characteristic of fouling organism extracellular proteases on the controlled-release material, the purpose of adjusting the release of antifouling agents adaptively with the change of fouling organisms in off-season/peak-season can be achieved, prolonging the service life of the antifouling coatings.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: May 11, 2021
    Assignee: LUOYANG SHIP MATERIAL RESEARCH INSTITUTE
    Inventors: Li Wang, Cunguo Lin, Jiyong Zheng
  • Patent number: 10993917
    Abstract: There is provided a nanocomplex having a core-shell structure. The shell of the nanocomplex comprises a functionalized hyaluronic acid while the core of the nanocomplex comprises a flavonoid encapsulating a metal-containing compound. Preferably, the flavonoid is epigallocatechin gallate (EGCG) and the hyaluronic acid is thiol-functionalized and subsequently conjugated to the flavonoid. There is also provided a method of forming the nanocomplex, a pharmaceutical composition comprising the nanocomplex, medical uses of the nanocomplex and a method of treating a patient, preferably with cancer using the nanocomplex.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: May 4, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Motoichi Kurisawa, Ki Hyun Bae, Susi Tan
  • Patent number: 10973776
    Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: April 13, 2021
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Anjali A. Hirani, Yashwant V. Pathak
  • Patent number: 10973759
    Abstract: A process for the manufacture of semi-plastic pharmaceutical unit doses using a rotary moulding machine and semi-plastic pharmaceutical dosage units obtained by this process.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: April 13, 2021
    Assignee: Intervet Inc.
    Inventors: Dominique Kluger, Albin Hauler, Carsten Schmidt, David Schroeckenfuchs, Niki Waldron
  • Patent number: 10953025
    Abstract: The present invention relates to compositions, devices and methods of delayed and sustained release of energy molecules for brain function. The composition comprises an energy molecule required for human brain function; wherein the release of the energy molecule is delayed and then sustained over a period of time. The methods comprise administering the composition subject in need thereof immediately prior to going to sleep. The present invention also relates to systems for brain stimulation during sleep and methods of use thereof. The system comprises a brain stimulation module and at least one of a brain energy source, a hypnotic source, or both. The methods involve administering to a subject a brain energy molecule, a hypnotic, or both and providing to the subject during restorative sleep a sensory stimulation.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: March 23, 2021
    Assignee: Able Cerebral, LLC
    Inventor: Jun Xia
  • Patent number: 10918601
    Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally aministering the compositions, such as intranasally or intravaginally.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: February 16, 2021
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Maynard Emanuel Lichty, Garry T. Gwozdz
  • Patent number: 10881710
    Abstract: The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: January 5, 2021
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventor: David Bar-Or
  • Patent number: 10874605
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 29, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Thierry Nivaggioli, James Jane-Guo Shiah, Qing Lin
  • Patent number: 10864154
    Abstract: The present invention discloses a synergistic composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids for use as a skin lightening agent. The invention also discloses a method of inhibiting melanin biosynthesis and tyrosinase activity in mammalian skin cells using a composition comprising 3-O-ethyl-ascorbic acid and tetrahydrocurcuminoids.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: December 15, 2020
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
  • Patent number: 10835512
    Abstract: Compositions and methods for the treatment of respiratory syncytial virus infections are provided.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: November 17, 2020
    Assignee: Respivant Sciences GmbH
    Inventors: Pravin Soni, William Gerhart, Manfred Keller, Ahmet Tutuncu
  • Patent number: 10828321
    Abstract: Formulations containing reactive oxygen species (ROS), processes for making these formulations, and methods of using these formulations are described. The formulations can include gels or hydrogels that contain at least one reactive oxygen species (ROS). The formulations can include a composition containing a reduced species (RS) and a reactive oxygen species (ROS). The formulations can also contain a rheology modifier and can include gels or hydrogels. Methods of preparing the formulations can include preparing a composition. Compositions can be prepared by providing water, purifying the water to produce ultra-pure water, combining sodium chloride to the ultra-pure water to create salinated water, and electrolyzing the salinated water at a temperature between about 4.5 to about 5.8° C.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: November 10, 2020
    Assignee: RDG HOLDINGS, INC.
    Inventor: Andrew Hoover
  • Patent number: 10765617
    Abstract: Disclosed herein is a personal care conditioning and/or styling composition for keratin substrate comprising: (A) at least one conditioning and/or styling copolymer obtained from polymerizing: (i) about 0.1 wt. % to 99.9 wt. % of at least one cationic or pseudo-cationic monomer selected from the group consisting of acrylamidopropyl trimethylammonium chloride (APT AC) and/or diallyl dimethyl ammonium chloride (DADMAC); and (ii) about 0.1 wt. % to 99.9 wt. % of at least one monomer comprising at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety; (B) at least one cosmetically acceptable excipient; and (C) optionally, at least one effective amount of personal care active ingredient. Also disclose is a process for preparing such composition and method of use thereof.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: September 8, 2020
    Assignee: ISP INVESTMENTS LLC
    Inventors: Amna Khatun, David Petty, Lidia Kulcsar
  • Patent number: 10751270
    Abstract: The invention relates to a new composition in the form of a translucent, advantageously transparent, gel, without triethanolamine, comprising at least a fatty body in the form of an oleic acid an aqueous phase; and a base or a mixture of bases. The invention also relates to compositions, advantageously cosmetic compositions, comprising said gel base, such as a shaving gel. The invention also relates to a method for preparing said gel base, a shaving method, the use of said gel base and a shaving kit.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: August 25, 2020
    Assignees: SUDCOSMETICS, LABORATOIRE SANDRALEX
    Inventors: Alex Chauvin, Laurent Dodet, Jean-Marie Total
  • Patent number: 10729663
    Abstract: The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 4, 2020
    Assignee: University of South Florida
    Inventors: Vijaykumar Bhadabhai Sutariya, Anjali A. Hirani, Yashwant V. Pathak
  • Patent number: 10702607
    Abstract: Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 7, 2020
    Assignee: G.L. PHARMA GMBH
    Inventors: Georg Guebitz, Katrin Greimel, Martin Brandauer, Daniela Huber, Klaus Bleymaier, Wolfgang Kroutil, Doris Lechner, Christof Wachter, Harald Wagner, Heimo Winkler
  • Patent number: 10695295
    Abstract: Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 ?m, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 ?m; at least 50% of the spray-dried particles have a particle size of at least about 15 ?m; and at least 90% of the spray-dried particles have a particle size of up to about 55 ?m. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: June 30, 2020
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Maynard Emanuel Lichty, Garry T. Gwozdz
  • Patent number: 10695734
    Abstract: Provided herein are microcapsules as core-shell-particles, including a polymeric shell, a method of making them, a dispersion of the microcapsules in a liquid medium and a method of using thereof. The microcapsules include a core that contains a hydrophilic component.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: June 30, 2020
    Assignee: BASF SE
    Inventors: Yannick Fuchs, Helmut Witteler, Matthias Bratz
  • Patent number: 10695460
    Abstract: Subject of the invention is a composition comprising: (a) at least one film-forming polymer, which does not comprise silicon, (b) at least one organic UV filter, and (c) at least one organic solvent, wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), and wherein the ratio of the total amounts of organic UV filters (b) to film-forming polymers (a) is below 6.5. The invention also relates to compositions for therapy, uses of the composition, devices and methods.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: June 30, 2020
    Assignee: Siniq GmbH
    Inventors: Juerg Schmid, Andreas Supersaxo